{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:10:00Z","timestamp":1779199800467,"version":"3.51.4"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Fondation d\u2019Entreprise Bristol-Myers Squibb pour la recherche en Immuno-Oncologie"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-026-01796-1","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:31:38Z","timestamp":1779197498000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting GD2 with CAR-T Cell Therapy in Neuroblastoma: Updates, Challenges, and Future Perspectives"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8009-4611","authenticated-orcid":false,"given":"Hortense","family":"Alliot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9728-2576","authenticated-orcid":false,"given":"Pierre","family":"Machy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1771-9025","authenticated-orcid":false,"given":"Marc-David","family":"Leclair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8217-778X","authenticated-orcid":false,"given":"St\u00e9phane","family":"Birkle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5875-6121","authenticated-orcid":false,"given":"S\u00e9bastien","family":"Faraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"1796_CR1","doi-asserted-by":"publisher","unstructured":"Yue C, Zhang Q, Sun F, Pan Q. Neoplasia. 2025;60:101122. https:\/\/doi.org\/10.1016\/j.neo.2025.101122. Global, regional and national burden of neuroblastoma and other peripheral nervous system tumors, 1990 to 2021 and predictions to 2035: visualizing epidemiological characteristics based on GBD 2021.","DOI":"10.1016\/j.neo.2025.101122"},{"key":"1796_CR2","doi-asserted-by":"publisher","first-page":"e30732","DOI":"10.1002\/pbc.30732","volume":"71","author":"K Campbell","year":"2024","unstructured":"Campbell K, Siegel DA, Umaretiya PJ, Dai S, Heczey A, Lupo PJ, et al. A comprehensive analysis of neuroblastoma incidence, survival, and racial and ethnic disparities from 2001 to 2019. Pediatr Blood Cancer. 2024;71:e30732. https:\/\/doi.org\/10.1002\/pbc.30732.","journal-title":"Pediatr Blood Cancer"},{"key":"1796_CR3","doi-asserted-by":"publisher","first-page":"e927218","DOI":"10.12659\/MSM.927218","volume":"26","author":"P Yan","year":"2020","unstructured":"Yan P, Qi F, Bian L, Xu Y, Zhou J, Hu J, et al. Comparison of Incidence and Outcomes of Neuroblastoma in Children, Adolescents, and Adults in the United States: A Surveillance, Epidemiology, and End Results (SEER) Program Population Study. Med Sci Monit. 2020;26:e927218. https:\/\/doi.org\/10.12659\/MSM.927218.","journal-title":"Med Sci Monit"},{"key":"1796_CR4","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1200\/GO.21.00054","volume":"7","author":"J van Heerden","year":"2021","unstructured":"van Heerden J, Abraham N, Schoeman J, Reynders D, Singh E, Kruger M. Reporting Incidences of Neuroblastoma in Various Resource Settings. JCO Glob Oncol. 2021;7:947\u201364. https:\/\/doi.org\/10.1200\/GO.21.00054.","journal-title":"JCO Glob Oncol"},{"key":"1796_CR5","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1177\/1060028016632013","volume":"50","author":"C Ploessl","year":"2016","unstructured":"Ploessl C, Pan A, Maples KT, Lowe DK. Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma. Ann Pharmacother. 2016;50:416\u201322. https:\/\/doi.org\/10.1177\/1060028016632013.","journal-title":"Ann Pharmacother"},{"key":"1796_CR6","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s40265-021-01467-4","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham A, Naxitamab. First Approval Drugs. 2021;81:291\u20136. https:\/\/doi.org\/10.1007\/s40265-021-01467-4.","journal-title":"First Approval Drugs"},{"key":"1796_CR7","first-page":"440","volume":"46","author":"ZL Wu","year":"1986","unstructured":"Wu ZL, Schwartz E, Seeger R, Ladisch S. Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res janv. 1986;46:440\u20133.","journal-title":"Cancer Res janv"},{"key":"1796_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0005-2760(94)90034-5","volume":"1214","author":"L Svennerholm","year":"1994","unstructured":"Svennerholm L, Bostr\u00f6m K, Fredman P, Jungbjer B, Lekman A, M\u00e5nsson JE, et al. Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. Biochim Biophys Acta. 1994;1214:115\u201323. https:\/\/doi.org\/10.1016\/0005-2760(94)90034-5.","journal-title":"Biochim Biophys Acta"},{"key":"1796_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0022-510X(97)05390-2","volume":"149","author":"N Yuki","year":"1997","unstructured":"Yuki N, Yamada M, Tagawa Y, Takahashi H, Handa S. Pathogenesis of the neurotoxicity caused by anti-GD2 antibody therapy. J Neurol Sci. 1997;149:127\u201330.","journal-title":"J Neurol Sci"},{"key":"1796_CR10","doi-asserted-by":"publisher","first-page":"e25220","DOI":"10.1371\/journal.pone.0025220","volume":"6","author":"N Alvarez-Rueda","year":"2011","unstructured":"Alvarez-Rueda N, Desselle A, Cochonneau D, Chaumette T, Clemenceau B, Leprieur S, et al. A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity. PLoS ONE. 2011;6:e25220. https:\/\/doi.org\/10.1371\/journal.pone.0025220.","journal-title":"PLoS ONE"},{"key":"1796_CR11","doi-asserted-by":"publisher","first-page":"1249929","DOI":"10.3389\/fphar.2023.1249929","volume":"14","author":"P Machy","year":"2023","unstructured":"Machy P, Mortier E, Birkl\u00e9 S. Biology of GD2 ganglioside: implications for cancer immunotherapy. Front Pharmacol. 2023;14:1249929. https:\/\/doi.org\/10.3389\/fphar.2023.1249929.","journal-title":"Front Pharmacol"},{"key":"1796_CR12","doi-asserted-by":"publisher","first-page":"1382931","DOI":"10.3389\/fimmu.2024.1382931","volume":"15","author":"S Di Matteo","year":"2024","unstructured":"Di Matteo S, Bilotta MT, Pelosi A, Haas D, Theinert T, Weber G, et al. Transition to a mesenchymal state in neuroblastoma may be characterized by a high expression of GD2 and by the acquisition of immune escape from NK cells. Front Immunol. 2024;15:1382931. https:\/\/doi.org\/10.3389\/fimmu.2024.1382931.","journal-title":"Front Immunol"},{"key":"1796_CR13","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1182\/blood.V75.7.1564.1564","volume":"75","author":"L Valentino","year":"1990","unstructured":"Valentino L, Moss T, Olson E, Wang HJ, Elashoff R, Ladisch S. Shed tumor gangliosides and progression of human neuroblastoma. Blood. 1990;75:1564\u20137.","journal-title":"Blood"},{"key":"1796_CR14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/BF00731471","volume":"13","author":"R Li","year":"1996","unstructured":"Li R, Gage D, McKallip R, Ladisch S. Structural characterization and in vivo immunosuppressive activity of neuroblastoma GD2. Glycoconj J. 1996;13:385\u20139. https:\/\/doi.org\/10.1007\/BF00731471.","journal-title":"Glycoconj J"},{"key":"1796_CR15","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","volume":"363","author":"AL Yu","year":"2010","unstructured":"Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324\u201334. https:\/\/doi.org\/10.1056\/NEJMoa0911123.","journal-title":"N Engl J Med"},{"key":"1796_CR16","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S1470-2045(18)30578-3","volume":"19","author":"R Ladenstein","year":"2018","unstructured":"Ladenstein R, P\u00f6tschger U, Valteau-Couanet D, Luksch R, Castel V, Yaniv I. Interleukin 2 with anti-GD2 antibody ch14.18\/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1\/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol d\u00e9c. 2018;19:1617\u201329.","journal-title":"Lancet Oncol d\u00e9c"},{"key":"1796_CR17","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","volume":"15","author":"MA Cheever","year":"2009","unstructured":"Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15:5323\u201337. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0737.","journal-title":"Clin Cancer Res"},{"key":"1796_CR18","first-page":"1098","volume":"47","author":"K Mujoo","year":"1987","unstructured":"Mujoo K, Cheresh DA, Yang HM, Reisfeld RA. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res. 1987;47:1098\u2013104.","journal-title":"Cancer Res"},{"key":"1796_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/07357900601130763","volume":"25","author":"S Modak","year":"2007","unstructured":"Modak S, Cheung N-KV. Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest. 2007;25:67\u201377. https:\/\/doi.org\/10.1080\/07357900601130763.","journal-title":"Cancer Invest"},{"key":"1796_CR20","doi-asserted-by":"publisher","first-page":"e1433518","DOI":"10.1080\/2162402X.2018.1433518","volume":"7","author":"C Quintarelli","year":"2018","unstructured":"Quintarelli C, Orlando D, Boffa I, Guercio M, Polito VA, Petretto A, et al. Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma. Oncoimmunology. 2018;7:e1433518. https:\/\/doi.org\/10.1080\/2162402X.2018.1433518.","journal-title":"Oncoimmunology"},{"key":"1796_CR21","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med juin. 2015;21:581\u201390.","journal-title":"Nat Med juin"},{"key":"1796_CR22","doi-asserted-by":"publisher","first-page":"eaba1786","DOI":"10.1126\/science.aba1786","volume":"372","author":"EW Weber","year":"2021","unstructured":"Weber EW, Parker KR, Sotillo E, Lynn RC, Anbunathan H, Lattin J, et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science. 2021;372:eaba1786. https:\/\/doi.org\/10.1126\/science.aba1786.","journal-title":"Science"},{"key":"1796_CR23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn RC, Weber EW, Sotillo E, Gennert D, Xu P, Good Z, et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature. 2019;576:293\u2013300. https:\/\/doi.org\/10.1038\/s41586-019-1805-z.","journal-title":"Nature"},{"key":"1796_CR24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1158\/2326-6066.CIR-17-0211","volume":"6","author":"SA Richman","year":"2018","unstructured":"Richman SA, Nunez-Cruz S, Moghimi B, Li LZ, Gershenson ZT, Mourelatos Z. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model. Cancer Immunol Res janv. 2018;6:36\u201346.","journal-title":"Cancer Immunol Res janv"},{"key":"1796_CR25","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1158\/2326-6066.CIR-18-0089","volume":"6","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Weber EW, Lynn RC, Xu P, Mackall CL. Neurotoxicity Associated with a High-Affinity GD2 CAR-Letter. Cancer Immunol Res. 2018;6:494\u20135. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0089.","journal-title":"Cancer Immunol Res"},{"key":"1796_CR26","doi-asserted-by":"publisher","first-page":"e1320625","DOI":"10.1080\/2162402X.2017.1320625","volume":"6","author":"SS Hoseini","year":"2017","unstructured":"Hoseini SS, Dobrenkov K, Pankov D, Xu XL, Cheung N-KV. Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2. Oncoimmunology. 2017;6:e1320625. https:\/\/doi.org\/10.1080\/2162402X.2017.1320625.","journal-title":"Oncoimmunology"},{"key":"1796_CR27","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","volume":"637","author":"M Monje","year":"2025","unstructured":"Monje M, Mahdi J, Majzner R, Yeom KW, Schultz LM, Richards RM, et al. Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. Nature. 2025;637:708\u201315. https:\/\/doi.org\/10.1038\/s41586-024-08171-9.","journal-title":"Nature"},{"key":"1796_CR28","doi-asserted-by":"publisher","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","volume":"118","author":"CU Louis","year":"2011","unstructured":"Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011;118:6050\u20136.","journal-title":"Blood"},{"key":"1796_CR29","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.1882","volume":"14","author":"MA Pule","year":"2008","unstructured":"Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14:1264\u201370. https:\/\/doi.org\/10.1038\/nm.1882.","journal-title":"Nat Med"},{"key":"1796_CR30","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/s41591-025-03513-0","volume":"31","author":"C-H Li","year":"2025","unstructured":"Li C-H, Sharma S, Heczey AA, Woods ML, Steffin DHM, Louis CU, et al. Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma. Nat Med. 2025;31:1125\u20139. https:\/\/doi.org\/10.1038\/s41591-025-03513-0.","journal-title":"Nat Med"},{"key":"1796_CR31","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","volume":"25","author":"A Heczey","year":"2017","unstructured":"Heczey A, Louis CU, Savoldo B, Dakhova O, Durett A, Grilley B. CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Therapy sept. 2017;25:2214\u201324.","journal-title":"Mol Therapy sept"},{"key":"1796_CR32","doi-asserted-by":"crossref","unstructured":"Straathof K, Flutter B, Wallace R, Jain N, Loka T, Depani S. Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma. Sci Transl Med. 2020;12:571.","DOI":"10.1126\/scitranslmed.abd6169"},{"key":"1796_CR33","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1007\/s00432-021-03839-5","volume":"148","author":"L Yu","year":"2022","unstructured":"Yu L, Huang L, Lin D, Lai X, Wu L, Liao X, et al. GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and\/or recurrent neuroblastoma in pediatric patients. J Cancer Res Clin Oncol. 2022;148:2643\u201352. https:\/\/doi.org\/10.1007\/s00432-021-03839-5.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1796_CR34","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, et al. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. N Engl J Med. 2023;388:1284\u201395. https:\/\/doi.org\/10.1056\/NEJMoa2210859.","journal-title":"N Engl J Med"},{"key":"1796_CR35","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/s41591-024-03449-x","volume":"31","author":"C Quintarelli","year":"2025","unstructured":"Quintarelli C, Del Bufalo F, De Ioris MA, Guercio M, Algeri M, Pagliara D, et al. Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma. Nat Med. 2025;31:849\u201360. https:\/\/doi.org\/10.1038\/s41591-024-03449-x.","journal-title":"Nat Med"},{"key":"1796_CR36","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41591-020-1074-2","volume":"26","author":"A Heczey","year":"2020","unstructured":"Heczey A, Courtney AN, Montalbano A, Robinson S, Liu K, Li M. Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. Nat Med nov. 2020;26:1686\u201390.","journal-title":"Nat Med nov"},{"key":"1796_CR37","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","volume":"29","author":"A Heczey","year":"2023","unstructured":"Heczey A, Xu X, Courtney AN, Tian G, Barragan GA, Guo L, et al. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med. 2023;29:1379\u201388. https:\/\/doi.org\/10.1038\/s41591-023-02363-y.","journal-title":"Nat Med"},{"key":"1796_CR38","doi-asserted-by":"publisher","first-page":"e010156","DOI":"10.1136\/jitc-2024-010156","volume":"13","author":"G Tian","year":"2025","unstructured":"Tian G, Courtney AN, Yu H, Bhar S, Xu X, Barrag\u00e1n GA, et al. Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15. J Immunother Cancer. 2025;13:e010156. https:\/\/doi.org\/10.1136\/jitc-2024-010156.","journal-title":"J Immunother Cancer"},{"key":"1796_CR39","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s40001-025-03764-0","volume":"31","author":"MA Habibi","year":"2026","unstructured":"Habibi MA, Zand A, Robat-Jazi B, Khodadadiyan A, Dashti M, Nejati N, et al. The safety and efficacy of GD2-targeted CAR-T cells in patients with neuroblastoma: a systematic review and meta-analysis. Eur J Med Res. 2026;31:261. https:\/\/doi.org\/10.1186\/s40001-025-03764-0.","journal-title":"Eur J Med Res"},{"key":"1796_CR40","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/ng.2529","volume":"45","author":"TJ Pugh","year":"2013","unstructured":"Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013;45:279\u201384. https:\/\/doi.org\/10.1038\/ng.2529.","journal-title":"Nat Genet"},{"key":"1796_CR41","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s00262-004-0603-z","volume":"54","author":"M W\u00f6lfl","year":"2005","unstructured":"W\u00f6lfl M, Jungbluth AA, Garrido F, Cabrera T, Meyen-Southard S, Spitz R, et al. Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunol Immunother. 2005;54:400\u20136. https:\/\/doi.org\/10.1007\/s00262-004-0603-z.","journal-title":"Cancer Immunol Immunother"},{"key":"1796_CR42","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/1479-5876-9-170","volume":"9","author":"M Gowda","year":"2011","unstructured":"Gowda M, Godder K, Kmieciak M, Worschech A, Ascierto M-L, Wang E, et al. Distinct signatures of the immune responses in low risk versus high risk neuroblastoma. J Transl Med. 2011;9:170. https:\/\/doi.org\/10.1186\/1479-5876-9-170.","journal-title":"J Transl Med"},{"key":"1796_CR43","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1200\/JCO.2011.40.9169","volume":"30","author":"S Asgharzadeh","year":"2012","unstructured":"Asgharzadeh S, Salo JA, Ji L, Oberthuer A, Fischer M, Berthold F, et al. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol. 2012;30:3525\u201332. https:\/\/doi.org\/10.1200\/JCO.2011.40.9169.","journal-title":"J Clin Oncol"},{"key":"1796_CR44","doi-asserted-by":"publisher","first-page":"2146860","DOI":"10.1080\/2162402X.2022.2146860","volume":"11","author":"K Louault","year":"2022","unstructured":"Louault K, Porras T, Lee M-H, Muthugounder S, Kennedy RJ, Blavier L, et al. Fibroblasts and macrophages cooperate to create a pro-tumorigenic and immune resistant environment via activation of TGF-\u03b2\/IL-6 pathway in neuroblastoma. Oncoimmunology. 2022;11:2146860. https:\/\/doi.org\/10.1080\/2162402X.2022.2146860.","journal-title":"Oncoimmunology"},{"key":"1796_CR45","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1002\/cncr.30724","volume":"123","author":"RG Majzner","year":"2017","unstructured":"Majzner RG, Simon JS, Grosso JF, Martinez D, Pawel BR, Santi M, et al. Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. Cancer. 2017;123:3807\u201315. https:\/\/doi.org\/10.1002\/cncr.30724.","journal-title":"Cancer"},{"key":"1796_CR46","doi-asserted-by":"publisher","first-page":"15806","DOI":"10.3390\/ijms242115806","volume":"24","author":"S Sharma","year":"2023","unstructured":"Sharma S, Sauer T, Omer BA, Shum T, Rollins LA, Rooney CM. Constitutive Interleukin-7 Cytokine Signaling Enhances the Persistence of Epstein-Barr Virus-Specific T-Cells. Int J Mol Sci. 2023;24:15806. https:\/\/doi.org\/10.3390\/ijms242115806.","journal-title":"Int J Mol Sci"},{"key":"1796_CR47","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1172\/JCI37869","volume":"119","author":"L Song","year":"2009","unstructured":"Song L, Asgharzadeh S, Salo J, Engell K, Wu H, Sposto R, et al. Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J Clin Invest. 2009;119:1524\u201336. https:\/\/doi.org\/10.1172\/JCI37869.","journal-title":"J Clin Invest"},{"key":"1796_CR48","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1182\/blood-2013-11-541235","volume":"124","author":"A Heczey","year":"2014","unstructured":"Heczey A, Liu D, Tian G, Courtney AN, Wei J, Marinova E. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood. 2014;124:2824\u201333.","journal-title":"Blood"},{"key":"1796_CR49","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1006\/excr.1997.3619","volume":"234","author":"F Chang","year":"1997","unstructured":"Chang F, Li R, Ladisch S. Shedding of gangliosides by human medulloblastoma cells. Exp Cell Res. 1997;234:341\u20136. https:\/\/doi.org\/10.1006\/excr.1997.3619.","journal-title":"Exp Cell Res"},{"key":"1796_CR50","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/ijc.1457","volume":"94","author":"C Rossig","year":"2001","unstructured":"Rossig C, Bollard CM, Nuchtern JG, Merchant DA, Brenner MK. Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer. 2001;94:228\u201336. https:\/\/doi.org\/10.1002\/ijc.1457.","journal-title":"Int J Cancer"},{"key":"1796_CR51","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/CJI.0b013e31819b7c8e","volume":"32","author":"JA Westwood","year":"2009","unstructured":"Westwood JA, Murray WK, Trivett M, Haynes NM, Solomon B, Mileshkin L, et al. The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum. J Immunother. 2009;32:292\u2013301. https:\/\/doi.org\/10.1097\/CJI.0b013e31819b7c8e.","journal-title":"J Immunother"},{"key":"1796_CR52","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/sj.gt.3300813","volume":"6","author":"A Hombach","year":"1999","unstructured":"Hombach A, Koch D, Sircar R, Heuser C, Diehl V, Kruis W, et al. A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA. Gene Ther. 1999;6:300\u20134. https:\/\/doi.org\/10.1038\/sj.gt.3300813.","journal-title":"Gene Ther"},{"key":"1796_CR53","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","volume":"2","author":"K Hirabayashi","year":"2021","unstructured":"Hirabayashi K, Du H, Xu Y, Shou P, Zhou X, Fuc\u00e1 G, et al. Dual Targeting CAR-T Cells with Optimal Costimulation and Metabolic Fitness enhance Antitumor Activity and Prevent Escape in Solid Tumors. Nat Cancer. 2021;2:904\u201318. https:\/\/doi.org\/10.1038\/s43018-021-00244-2.","journal-title":"Nat Cancer"},{"key":"1796_CR54","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1177\/1093526617723972","volume":"21","author":"T Terzic","year":"2018","unstructured":"Terzic T, Cordeau M, Herblot S, Teira P, Cournoyer S, Beaunoyer M, et al. Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy. Pediatr Dev Pathol. 2018;21:355\u201362. https:\/\/doi.org\/10.1177\/1093526617723972.","journal-title":"Pediatr Dev Pathol"},{"key":"1796_CR55","doi-asserted-by":"publisher","first-page":"e1394","DOI":"10.1002\/cnr2.1394","volume":"4","author":"M Wiebel","year":"2021","unstructured":"Wiebel M, Kailayangiri S, Altvater B, Meltzer J, Grobe K, Kupich S, et al. Surface expression of the immunotherapeutic target GD2 in osteosarcoma depends on cell confluency. Cancer Rep (Hoboken). 2021;4:e1394. https:\/\/doi.org\/10.1002\/cnr2.1394.","journal-title":"Cancer Rep (Hoboken)"},{"key":"1796_CR56","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1016\/j.febslet.2009.11.019","volume":"584","author":"J Yin","year":"2010","unstructured":"Yin J, Miyazaki K, Shaner RL, Merrill AH, Kannagi R. Altered sphingolipid metabolism induced by tumor hypoxia - new vistas in glycolipid tumor markers. FEBS Lett. 2010;584:1872\u20138. https:\/\/doi.org\/10.1016\/j.febslet.2009.11.019.","journal-title":"FEBS Lett"},{"key":"1796_CR57","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s43018-022-00405-x","volume":"3","author":"NW Mabe","year":"2022","unstructured":"Mabe NW, Huang M, Dalton GN, Alexe G, Schaefer DA, Geraghty AC, et al. Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1. Nat Cancer. 2022;3:976\u201393. https:\/\/doi.org\/10.1038\/s43018-022-00405-x.","journal-title":"Nat Cancer"},{"key":"1796_CR58","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1021\/bi00004a012","volume":"34","author":"S Ladisch","year":"1995","unstructured":"Ladisch S, Hasegawa A, Li R, Kiso M. Immunosuppressive activity of chemically synthesized gangliosides. Biochemistry. 1995;34:1197\u2013202. https:\/\/doi.org\/10.1021\/bi00004a012.","journal-title":"Biochemistry"},{"key":"1796_CR59","doi-asserted-by":"publisher","first-page":"7141","DOI":"10.1038\/s41467-024-51337-2","volume":"15","author":"G Pascual-Pasto","year":"2024","unstructured":"Pascual-Pasto G, McIntyre B, Hines MG, Giudice AM, Garcia-Gerique L, Hoffmann J, et al. CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma. Nat Commun. 2024;15:7141. https:\/\/doi.org\/10.1038\/s41467-024-51337-2.","journal-title":"Nat Commun"},{"key":"1796_CR60","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41467-020-20785-x","volume":"12","author":"B Moghimi","year":"2021","unstructured":"Moghimi B, Muthugounder S, Jambon S, Tibbetts R, Hung L, Bassiri H, et al. Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. Nat Commun. 2021;12:511. https:\/\/doi.org\/10.1038\/s41467-020-20785-x.","journal-title":"Nat Commun"},{"key":"1796_CR61","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jcyt.2022.10.007","volume":"25","author":"E Halliwell","year":"2023","unstructured":"Halliwell E, Vitali A, Muller H, Alonso-Ferrero M, Barisa M, Gavriil A, et al. Targeting of low ALK antigen density neuroblastoma using AND logic-gate engineered CAR-T cells. Cytotherapy. 2023;25:46\u201358. https:\/\/doi.org\/10.1016\/j.jcyt.2022.10.007.","journal-title":"Cytotherapy"},{"key":"1796_CR62","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1186\/s12885-019-6131-1","volume":"19","author":"L Andersch","year":"2019","unstructured":"Andersch L, Radke J, Klaus A, Schwiebert S, Winkler A, Schumann E, et al. CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing. BMC Cancer. 2019;19:895. https:\/\/doi.org\/10.1186\/s12885-019-6131-1.","journal-title":"BMC Cancer"},{"key":"1796_CR63","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.jcyt.2024.05.023","volume":"26","author":"H Wu","year":"2024","unstructured":"Wu H, Zhang G, Liu Z, Liu W, Wang X, Zhao Y. Enhanced anti-tumor activity mediated by combination chimeric antigen receptor T cells targeting GD2 and GPC2 in high-risk neuroblastoma. Cytotherapy. 2024;26:1308\u201319. https:\/\/doi.org\/10.1016\/j.jcyt.2024.05.023.","journal-title":"Cytotherapy"},{"key":"1796_CR64","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1097\/CJI.0b013e3181ee6675","volume":"33","author":"JA Craddock","year":"2010","unstructured":"Craddock JA, Lu A, Bear A, Pule M, Brenner MK, Rooney CM, et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother. 2010;33:780\u20138. https:\/\/doi.org\/10.1097\/CJI.0b013e3181ee6675.","journal-title":"J Immunother"},{"key":"1796_CR65","doi-asserted-by":"publisher","first-page":"734593","DOI":"10.3389\/fonc.2021.734593","volume":"11","author":"G Li","year":"2021","unstructured":"Li G, Zhang Q, Han Z, Zhu Y, Shen H, Liu Z, et al. IL-7 and CCR2b Co-Expression-Mediated Enhanced CAR-T Survival and Infiltration in Solid Tumors. Front Oncol. 2021;11:734593. https:\/\/doi.org\/10.3389\/fonc.2021.734593.","journal-title":"Front Oncol"},{"key":"1796_CR66","doi-asserted-by":"publisher","first-page":"eads3403","DOI":"10.1126\/sciadv.ads3403","volume":"11","author":"KC Vogt","year":"2025","unstructured":"Vogt KC, Silberman PC, Lin Q, Han JE, Laflin A, Gellineau HA, et al. Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity. Sci Adv. 2025;11:eads3403. https:\/\/doi.org\/10.1126\/sciadv.ads3403.","journal-title":"Sci Adv"},{"key":"1796_CR67","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1158\/1078-0432.CCR-18-1811","volume":"25","author":"Y Chen","year":"2019","unstructured":"Chen Y, Sun C, Landoni E, Metelitsa L, Dotti G, Savoldo B. Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15. Clin Cancer Res. 2019;25:2915\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1811.","journal-title":"Clin Cancer Res"},{"key":"1796_CR68","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1158\/1078-0432.CCR-23-3157","volume":"30","author":"L Fischer-Riepe","year":"2024","unstructured":"Fischer-Riepe L, Kailayangiri S, Zimmermann K, Pfeifer R, Aigner M, Altvater B, et al. Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers. Clin Cancer Res. 2024;30:3564\u201377. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3157.","journal-title":"Clin Cancer Res"},{"key":"1796_CR69","doi-asserted-by":"publisher","first-page":"839783","DOI":"10.3389\/fimmu.2022.839783","volume":"13","author":"W Glienke","year":"2022","unstructured":"Glienke W, Dragon AC, Zimmermann K, Martyniszyn-Eiben A, Mertens M, Abken H, et al. GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18. Front Immunol. 2022;13:839783. https:\/\/doi.org\/10.3389\/fimmu.2022.839783.","journal-title":"Front Immunol"},{"key":"1796_CR70","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1016\/j.cell.2025.02.035","volume":"188","author":"L Liu","year":"2025","unstructured":"Liu L, He P, Wang Y, Ma F, Li D, Bai Z, et al. Engineering sonogenetic EchoBack-CAR T cells. Cell. 2025;188:2621\u2013e263620. https:\/\/doi.org\/10.1016\/j.cell.2025.02.035.","journal-title":"Cell"},{"key":"1796_CR71","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.4049\/jimmunol.138.12.4539","volume":"138","author":"WE Seaman","year":"1987","unstructured":"Seaman WE, Sleisenger M, Eriksson E, Koo GC. Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1. Reduction in host defense against malignancy without loss of cellular or humoral immunity. J Immunol. 1987;138:4539\u201344.","journal-title":"J Immunol"},{"key":"1796_CR72","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3389\/fonc.2019.00196","volume":"9","author":"S Patel","year":"2019","unstructured":"Patel S, Burga RA, Powell AB, Chorvinsky EA, Hoq N, McCormack SE, et al. Beyond CAR T Cells: Other Cell-Based Immunotherapeutic Strategies Against Cancer. Front Oncol. 2019;9:196. https:\/\/doi.org\/10.3389\/fonc.2019.00196.","journal-title":"Front Oncol"},{"key":"1796_CR73","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/j.1582-4934.2011.01343.x","volume":"16","author":"R Esser","year":"2012","unstructured":"Esser R, M\u00fcller T, Stefes D, Kloess S, Seidel D, Gillies SD, et al. NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. J Cell Mol Med. 2012;16:569\u201381. https:\/\/doi.org\/10.1111\/j.1582-4934.2011.01343.x.","journal-title":"J Cell Mol Med"},{"key":"1796_CR74","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1158\/1078-0432.CCR-12-1243","volume":"19","author":"Y Liu","year":"2013","unstructured":"Liu Y, Wu H-W, Sheard MA, Sposto R, Somanchi SS, Cooper LJN, et al. Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy. Clin Cancer Res. 2013;19:2132\u201343. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1243.","journal-title":"Clin Cancer Res"},{"key":"1796_CR75","doi-asserted-by":"publisher","first-page":"20971","DOI":"10.1038\/s41598-024-70958-7","volume":"14","author":"R Mohseni","year":"2024","unstructured":"Mohseni R, Mahdavi Sharif P, Behfar M, Shojaei S, Shoae-Hassani A, Jafari L, et al. Phase I study of safety and efficacy of allogeneic natural killer cell therapy in relapsed\/refractory neuroblastomas post autologous hematopoietic stem cell transplantation. Sci Rep. 2024;14:20971. https:\/\/doi.org\/10.1038\/s41598-024-70958-7.","journal-title":"Sci Rep"},{"key":"1796_CR76","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00262-015-1669-5","volume":"64","author":"D Seidel","year":"2015","unstructured":"Seidel D, Shibina A, Siebert N, Wels WS, Reynolds CP, Huebener N, et al. Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma. Cancer Immunol Immunother. 2015;64:621\u201334. https:\/\/doi.org\/10.1007\/s00262-015-1669-5.","journal-title":"Cancer Immunol Immunother"},{"key":"1796_CR77","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41467-023-44310-y","volume":"15","author":"E Landoni","year":"2024","unstructured":"Landoni E, Woodcock MG, Barragan G, Casirati G, Cinella V, Stucchi S, et al. IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity. Nat Commun. 2024;15:89. https:\/\/doi.org\/10.1038\/s41467-023-44310-y.","journal-title":"Nat Commun"},{"key":"1796_CR78","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00262-025-04010-6","volume":"74","author":"W J\u00fcnemann","year":"2025","unstructured":"J\u00fcnemann W, Bley I, Rekowski L, Klokow M, Herppich S, M\u00fcller I, et al. GD2-CAR NK-92 cell activity against neuroblastoma cells is insusceptible to TIGIT knockout. Cancer Immunol Immunother. 2025;74:191. https:\/\/doi.org\/10.1007\/s00262-025-04010-6.","journal-title":"Cancer Immunol Immunother"},{"key":"1796_CR79","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1038\/s41598-020-59082-4","volume":"10","author":"N Mitwasi","year":"2020","unstructured":"Mitwasi N, Feldmann A, Arndt C, Koristka S, Berndt N, Jureczek J, et al. UniCAR-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells. Sci Rep. 2020;10:2141. https:\/\/doi.org\/10.1038\/s41598-020-59082-4.","journal-title":"Sci Rep"},{"key":"1796_CR80","doi-asserted-by":"publisher","first-page":"e004693","DOI":"10.1136\/jitc-2022-004693","volume":"10","author":"S Maddineni","year":"2022","unstructured":"Maddineni S, Silberstein JL, Sunwoo JB. Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells. J Immunother Cancer. 2022;10:e004693. https:\/\/doi.org\/10.1136\/jitc-2022-004693.","journal-title":"J Immunother Cancer"},{"key":"1796_CR81","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ymthe.2017.12.001","volume":"26","author":"A Capsomidis","year":"2018","unstructured":"Capsomidis A, Benthall G, Van Acker HH, Fisher J, Kramer AM, Abeln Z, et al. Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation. Mol Ther. 2018;26:354\u201365. https:\/\/doi.org\/10.1016\/j.ymthe.2017.12.001.","journal-title":"Mol Ther"},{"key":"1796_CR82","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/s0167-5699(00)01735-7","volume":"21","author":"DI Godfrey","year":"2000","unstructured":"Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol Today. 2000;21:573\u201383. https:\/\/doi.org\/10.1016\/s0167-5699(00)01735-7.","journal-title":"Immunol Today"},{"key":"1796_CR83","doi-asserted-by":"publisher","first-page":"e27572","DOI":"10.4161\/onci.27572","volume":"3","author":"JP Fisher","year":"2014","unstructured":"Fisher JP, Heuijerjans J, Yan M, Gustafsson K, Anderson J. \u03b3\u03b4 T cells for cancer immunotherapy: A systematic review of clinical trials. Oncoimmunology. 2014;3:e27572. https:\/\/doi.org\/10.4161\/onci.27572.","journal-title":"Oncoimmunology"},{"key":"1796_CR84","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1084\/jem.20031462","volume":"199","author":"LS Metelitsa","year":"2004","unstructured":"Metelitsa LS, Wu HW, Wang H, Yang Y, Warsi Z, Asgharzadeh S. Natural Killer T Cells Infiltrate Neuroblastomas Expressing the Chemokine CCL2. J Exp Med. 2004;199:1213\u201321.","journal-title":"J Exp Med"},{"key":"1796_CR85","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21:938\u201345. https:\/\/doi.org\/10.1038\/nm.3909.","journal-title":"Nat Med"},{"key":"1796_CR86","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/s41596-024-01077-w","volume":"20","author":"Y-R Li","year":"2025","unstructured":"Li Y-R, Zhou K, Lee D, Zhu Y, Halladay T, Yu J, et al. Generating allogeneic CAR-NKT cells for off-the-shelf cancer immunotherapy with genetically engineered HSP cells and feeder-free differentiation culture. Nat Protoc. 2025;20:1352\u201388. https:\/\/doi.org\/10.1038\/s41596-024-01077-w.","journal-title":"Nat Protoc"},{"key":"1796_CR87","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41587-024-02226-y","volume":"43","author":"Y-R Li","year":"2025","unstructured":"Li Y-R, Zhou Y, Yu J, Kim YJ, Li M, Lee D, et al. Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method. Nat Biotechnol. 2025;43:329\u201344. https:\/\/doi.org\/10.1038\/s41587-024-02226-y.","journal-title":"Nat Biotechnol"},{"key":"1796_CR88","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.stemcr.2022.12.012","volume":"18","author":"J Zhang","year":"2023","unstructured":"Zhang J, Webster S, Duffin B, Bernstein MN, Steill J, Swanson S, et al. Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies. Stem Cell Rep. 2023;18:585\u201396. https:\/\/doi.org\/10.1016\/j.stemcr.2022.12.012.","journal-title":"Stem Cell Rep"},{"key":"1796_CR89","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1172\/JCI35700","volume":"118","author":"S Hacein-Bey-Abina","year":"2008","unstructured":"Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118:3132\u201342. https:\/\/doi.org\/10.1172\/JCI35700.","journal-title":"J Clin Invest"},{"key":"1796_CR90","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nature09328","volume":"467","author":"M Cavazzana-Calvo","year":"2010","unstructured":"Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, et al. Transfusion independence and HMGA2 activation after gene therapy of human \u03b2-thalassaemia. Nature. 2010;467:318\u201322. https:\/\/doi.org\/10.1038\/nature09328.","journal-title":"Nature"},{"key":"1796_CR91","doi-asserted-by":"publisher","first-page":"132ra53","DOI":"10.1126\/scitranslmed.3003761","volume":"4","author":"J Scholler","year":"2012","unstructured":"Scholler J, Brady TL, Binder-Scholl G, Hwang W-T, Plesa G, Hege KM, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med. 2012;4:132ra53. https:\/\/doi.org\/10.1126\/scitranslmed.3003761.","journal-title":"Sci Transl Med"},{"key":"1796_CR92","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41591-018-0006-x","volume":"24","author":"CW Mount","year":"2018","unstructured":"Mount CW, Majzner RG, Sundaresh S, Arnold EP, Kadapakkam M, Haile S, et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas. Nat Med. 2018;24:572\u20139. https:\/\/doi.org\/10.1038\/s41591-018-0006-x.","journal-title":"Nat Med"},{"key":"1796_CR93","doi-asserted-by":"publisher","first-page":"1375833","DOI":"10.3389\/fimmu.2024.1375833","volume":"15","author":"L Garc\u00eda-Garc\u00eda","year":"2024","unstructured":"Garc\u00eda-Garc\u00eda L, G S\u00e1nchez E, Ivanova M, Pastora K, Alc\u00e1ntara-S\u00e1nchez C, Garc\u00eda-Mart\u00ednez J, et al. Choosing T-cell sources determines CAR-T cell activity in neuroblastoma. Front Immunol. 2024;15:1375833. https:\/\/doi.org\/10.3389\/fimmu.2024.1375833.","journal-title":"Front Immunol"},{"key":"1796_CR94","doi-asserted-by":"publisher","first-page":"101249","DOI":"10.1016\/j.omtm.2024.101249","volume":"32","author":"D Cappabianca","year":"2024","unstructured":"Cappabianca D, Pham D, Forsberg MH, Bugel M, Tommasi A, Lauer A, et al. Metabolic priming of GD2 TRAC-CAR T cells during manufacturing promotes memory phenotypes while enhancing persistence. Mol Ther Methods Clin Dev. 2024;32:101249. https:\/\/doi.org\/10.1016\/j.omtm.2024.101249.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1796_CR95","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1158\/2326-6066.CIR-14-0051","volume":"2","author":"N Singh","year":"2014","unstructured":"Singh N, Liu X, Hulitt J, Jiang S, June CH, Grupp SA, et al. Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma. Cancer Immunol Res. 2014;2:1059\u201370. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0051.","journal-title":"Cancer Immunol Res"},{"key":"1796_CR96","doi-asserted-by":"publisher","unstructured":"Foster JB, Madsen PJ, Harvey K, Griffin C, Stern A, Patterson L, et al. Transient mRNA CAR T cells targeting GD2 provide dose-adjusted efficacy against diffuse midline glioma and high grade glioma models. Neuro Oncol. 2025;noaf115. https:\/\/doi.org\/10.1093\/neuonc\/noaf115.","DOI":"10.1093\/neuonc\/noaf115"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01796-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01796-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01796-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:31:40Z","timestamp":1779197500000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-026-01796-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1796"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01796-1","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"10 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional Review Board Statement"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent<!--Emphasis Type='Bold' removed-->Statement"}},{"value":"SB and SF declare the following potential conflicts of interest related to this work. Some of the studies cited in this review are authored by SB and SF and are linked to patents held or pending by their affiliated institutions (Nantes University, Inserm, and CHU de Nantes). These patents are licensed to OGD2 Pharma (Nantes, France), but SB and SF do not receive royalties or financial benefits from these licenses. This disclosure is made to ensure transparency and does not affect the objectivity of the review.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"SB and SF declare the following potential conflicts of interest related to this work. Some of the studies cited in this review are authored by SB and SF and are linked to patents held or pending by their affiliated institutions (Nantes University, Inserm, and CHU de Nantes). These patents are licensed to OGD2 Pharma (Nantes, France), but SB and SF do not receive royalties or financial benefits from these licenses. This disclosure is made to ensure transparency and does not affect the objectivity of the review.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"55"}}